Persistence of antibodies 1 year after sequential administration of the 13-valent pneumococcal conjugate vaccine and the 23-valent pneumococcal polysaccharide …
B Schmoele-Thoma, M van Cleeff… - Human Vaccines & …, 2019 - Taylor & Francis
Vaccination with the 13-valent pneumococcal conjugate vaccine (PCV13) followed≥ 1 year
by the 23-valent pneumococcal polysaccharide vaccine (PPSV23) is recommended for …
by the 23-valent pneumococcal polysaccharide vaccine (PPSV23) is recommended for …
Retrospective cost-effectiveness of the 23-valent pneumococcal polysaccharide vaccination program in Australia
Abstract Background The Australian infant pneumococcal vaccination program was funded
in 2005 using the 7-valent pneumococcal conjugate vaccine (PCV7) and the 13-valent …
in 2005 using the 7-valent pneumococcal conjugate vaccine (PCV7) and the 13-valent …
The clinical effectiveness of pneumococcal vaccination:: a brief review
DS Fedson - Vaccine, 1999 - Elsevier
Randomized controlled trials have shown that pneumococcal polysaccharide vaccine is
efficacious in preventing pneumococcal bacteraemia and pneumococcal pneumonia in …
efficacious in preventing pneumococcal bacteraemia and pneumococcal pneumonia in …
Effects of sequential vs single pneumococcal vaccination on cardiovascular diseases among older adults: a population-based cohort study
Background Recommendations around the use of 23-valent pneumococcal polysaccharide
vaccine (PPSV23) and 13-valent pneumococcal conjugate vaccine (PCV13) seldom focus …
vaccine (PPSV23) and 13-valent pneumococcal conjugate vaccine (PCV13) seldom focus …
[引用][C] Pneumonia endpoints must be standardized for adult pneumococcal vaccine trials.
M Suzuki, K Morimoto - Vaccine, 2019 - europepmc.org
This is a comment on" Rethinking results from the Japanese 23-valent pneumococcal
polysaccharide vaccine randomized clinical trial." Vaccine. 2019 Aug 14; 37 (35): 4853 …
polysaccharide vaccine randomized clinical trial." Vaccine. 2019 Aug 14; 37 (35): 4853 …
Impact of the pneumococcal vaccine on long-term morbidity and mortality of adults at high risk for pneumonia
J Johnstone, DT Eurich, JK Minhas… - Clinical infectious …, 2010 - academic.oup.com
Background. There is debate surrounding the effectiveness of the 23-valent pneumococcal
polysaccharide vaccine (PPV). We determined whether PPV was associated with reduced …
polysaccharide vaccine (PPV). We determined whether PPV was associated with reduced …
Estimating the risk of recurrent invasive pneumococcal disease in Australia, 1991–2016
Background Individuals who experience an initial episode of invasive pneumococcal
disease (IPD) are at increased risk of recurrent episodes. However, the magnitude of risk …
disease (IPD) are at increased risk of recurrent episodes. However, the magnitude of risk …
Real-world effectiveness of pneumococcal vaccination in older adults: Cohort study using the UK Clinical Practice Research Datalink
Background The 23-valent pneumococcal polysaccharide vaccine (PPV23) is
recommended for UK older adults, but how age moderates effectiveness is unclear. Methods …
recommended for UK older adults, but how age moderates effectiveness is unclear. Methods …
[HTML][HTML] Increased invasive pneumococcal disease, North east England, UK
C Houseman, GJ Hughes, KE Chapman… - Emerging infectious …, 2017 - ncbi.nlm.nih.gov
Since April 2014, invasive pneumococcal disease incidence has increased substantially
across North East England, United Kingdom, reversing the decline that followed the 2006 …
across North East England, United Kingdom, reversing the decline that followed the 2006 …
Relative effectiveness of revaccination with 23-valent pneumococcal polysaccharide vaccine in preventing invasive pneumococcal disease in adult Aboriginal and …
Abstract Background Aboriginal and Torres Strait Islander (Indigenous) Australians have
high rates of invasive pneumococcal disease (IPD), with repeat doses of 23-valent …
high rates of invasive pneumococcal disease (IPD), with repeat doses of 23-valent …